FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.

As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...